Crescent Biopharma, Inc.
CBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,966,698 | $622,508 | $1,354,967 | $1,605,651 |
| - Cash | $133,265 | $152,645 | $5,614 | $10,720 |
| + Debt | $1,741 | $1,644 | $0 | $67 |
| Enterprise Value | $1,835,174 | $471,507 | $1,349,353 | $1,594,997 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$24,579 | -$20,717 | -$2,399 | -$5,314 |
| % Margin | – | – | – | – |
| Net Income | -$24,607 | -$21,790 | -$2,344 | -$7,223 |
| % Margin | – | – | – | – |
| EPS Diluted | -1,266.44 | -0.56 | -0.036 | -0.11 |
| % Growth | -226,050% | -1,442.7% | 67% | – |
| Operating Cash Flow | -$17,525 | -$22,161 | -$5,106 | -$3,701 |
| Capital Expenditures | -$586 | -$140 | $0 | $0 |
| Free Cash Flow | -$18,111 | -$22,301 | -$5,106 | -$3,701 |